Icon reports 26% annual increase in revenue

Icon — the Dublin-headquartered pharmaceutical services company — has reported “an encouraging start” to 2013, noting a 26% annualised increase in revenue and a more than doubling of operating profits for the first three months of the year.

The company — which de-listed from the Iseq towards the end of last year in order to take a full listing on New York’s Nasdaq exchange — yesterday reported operating income of $27.4m (€21m) for the first quarter of 2013; well up on the $11.7m figure recorded for the same period last year.

Diluted earnings per share, for the quarter, amounted to 36c (up from 15c, at the same point last year) and net revenue — up by 26% on a year-on-year basis — stood at $317m.